Month: June 2015

Nitrofurantoin – An Old Drug Resurrected Needs Prospective Scrutiny

Posted on by — No Comments ↓

When older drugs get reintroduced into clinical practice because pathogens have developed resistance to newer agents, it comes at the price of uncertainty. Often, older drugs were approved based on rather limited data, often considered incomplete by today’s standards.  Take colistin as an example: approved in the early 60ies, we still Continue reading Nitrofurantoin – An Old Drug Resurrected Needs Prospective Scrutiny→

Why Moxifloxacin’s Approval for Plague Is So Disturbing

Posted on by — No Comments ↓

PLEASE SHARE YOUR OPINION AND VOTE BELOW On May 8th, 2015 moxifloxacin/Avelox was approved for treatment of inhalational plague.[1]   We learn that the approval followed the ‘animal rule’ process, and that treatment with moxifloxacin was 100% effective in the African Green Monkey (AGM) model of lung infection.  By contrast, 0% of Continue reading Why Moxifloxacin’s Approval for Plague Is So Disturbing→

Tenofovir, BMD and Monitoring of Renal Function

Posted on by — No Comments ↓

The approved tenofovir / Viread label lists not only standard nucleoside-class side effects but also – since an update in 2012 – makes mention of diminished bone mineral density (BMD) in the Warnings / Precautions section. Demonstrating that a particular drug affects BMD in patients who are already at an increased risk Continue reading Tenofovir, BMD and Monitoring of Renal Function→